A Randomized Phase I Bioequivalence Clinical Trial of a Paediatric Fixed-Dose Combination Antiretroviral Reconstitutable Suspension in Healthy Adult Volunteers
Free accessResearch articleFirst published online February, 2013
A Randomized Phase I Bioequivalence Clinical Trial of a Paediatric Fixed-Dose Combination Antiretroviral Reconstitutable Suspension in Healthy Adult Volunteers
This study aimed to test the hypothesis that paediatric fixed-dose combination granule for reconstitution (comprising lamivudine/zidovudine/nevirapine 30/60/50 mg per 5 ml) as a test product is bioequivalent to the coadministered single entities of the reference products. Fixed-dose combination antiretroviral therapy provides adequate suppression of HIV-1 replication, provides barrier to the development of resistance, simplifies dosage regimen and improves adherence.
Methods
An open label, randomized, two-way crossover study was conducted on 24 healthy adults under fasted conditions, with a washout period of 14 days between treatments. A total of 15 blood samples were collected before dosing and up to 96 h post dosing. The drugs were extracted from plasma and analysed using a validated high performance liquid chromatography - ultraviolet method. Non-compartmental pharmacokinetic (PK) analysis was performed to obtain the PK parameters, maximum plasma concentration (Cmax), area under curve of plasma concentration–time curves from time zero to last measurable concentration (AUC0–t) and area under curve extrapolated to infinity (AUC0–∞). ANOVA test was performed to determine the effect of model factors on the PK parameters. The two one-sided t-tests were performed on the log-transformed data to determine the 90% CI for the ratio of test to reference PK parameters.
Results
The drugs were well tolerated and safe, with minimal adverse events. The ANOVA test indicated the absence of any significant effects (P>0.05) due to the model parameters. The 90% CI for the geometric mean ratio of test/ reference for Cmax, AUC0–t and AUC0–∞for lamivudine, zidovudine and nevirapine were within the 80–125% bioequivalence limits.
Conclusions
This single-dose randomized study found that the test and reference products met the criteria for bioequivalence in the fasting healthy adult volunteers.
References
1.
FrenchM., AminJ., RothN.Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: the OzCombo 2 study. HIV Clin Trials2002; 3: 177–185.
2.
PujariS.N., PatelA.K., NaikE.Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr2004; 37: 1566–1569.
3.
MarierJ.F., DimarcoM., GuilbaudR.Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products. J Clin Pharmacol2007; 47: 1381–1389.
4.
ChokephaibulkitK., CresseyT.R., CapparelliE.Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Antivir Ther2011; 16: 1287–1295.
5.
KasiryeP., KendallL., AdkisonK.Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clin Pharmacol Ther2012; 91: 272–280.
6.
MonifT., ReyarS., TiwariH.K.A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers. Arzneimittelforschung2009; 59: 104–108.
7.
KayitareE., VervaetC., NtawukulilyayoJ.D., SeminegaB., BortelV., RemonJ.P.Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications. Int J Pharm2009; 370: 41–46.
8.
Food and Drug Administration, Center for Drug Evaluation and Research.Guidance for industry: fixed dose combinations, co-packaged drug products, and single-entity versions of previously approved antiretroviral for treatment of HIV. (Updated 30 October 2006. Accessed 1 December 2012.) Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079742.pdf.
9.
WHO UNAIDS and UNESCO.Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. (Updated 28 September 2010. Accessed 1 December 2012.) Available from http://whqlibdoc.who.int/publications/2010/9789241500395_eng.pdf.
10.
HolmesC.B., CogginW., JamiesonD.Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA2010; 304: 313–320.
MerrillD.P., MoonisM., ChouT.C., HirschM.S.Lamivudine or stavudine in two-and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis1996; 173: 355–364.
13.
EssekuF., JoshiA., AdeyeyeM.C.Paediatric HIV/AIDS drug formulation development in academic institutions as a cost reduction strategy. International Pharmacy Journal2011; 2: 10–14.
14.
WaningB., DiedrichsenE., JambertE.The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children. BMC Pediatrics2010; 10: 1–14.
15.
World Medical Association General Assembly.WMA Declaration of Helsinki - Ethical principles for medical research involving human subjects. (Updated 30 October 2008. Accessed 2 December 2012.) Available from http://www.wma.net/en/30publications/10policies/b3/.
AdeyeyeM., EssekuF., JoshiA. inventors; Duquesne University, assignee. Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS. United States patent US 0117193A1 2011 May 19.
KleinbaumD.G., KupperL.L., NizamA., MullerK.E.Applied regression analysis and other multivariable methods. 4th ed.Belmont: Duxbury Press2008.
20.
JoshiA., EssekuF., SilvaL.Postmarketing in vitro/in vivo assessment of fixed dose combination products of first line antiretrovirals. J Pharm Sci2010; 99: 2655–2663.
21.
ChowS.C., LiuJ.Design and analysis of bioavailability and bioequivalence studies. 2nd ed.New York: Marcel Dekker2000.
22.
Food and Drug Administration, Center for Drug Evaluation and Research.Statistical approaches to establishing bioequivalence.2001. (Updated 31 January 2001. Accessed 1 December 2012.) Available at http://www.fda.gov/downloads/Drugs/…/Guidances/ucm070244.pdf.
23.
Combivir (lamivudine/zidovudine).Package insert2010. GlaxoSmithKlineResearch Triangle Park, NC, USA.
24.
Viramune (nevirapine).Package insert2011. Boehringer Ingelheim Pharmaceuticals Inc.Ridgefield CT, USA.
25.
LuzuriagaK., BrysonY., McSherryG.Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis1996; 174: 713–721.
26.
PollockL., ElseL., PoerksenG.Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. J Antimicrob Chemother2009; 64: 1251–1259.
27.
AngelA., PeischlR., HawiA.Low-voltage scanning electron microscope (LVSEM) determination of nevirapine crystal habit in a pharmaceutical.Proceedings of the 50th Annual Meeting of the Electron Microscopy Society of America. 16–22 April 1992, Boston, MA, USA. pp. 1326.
28.
WHO Paediatric Antiretroviral Working Group.Preferred antiretroviral medicines for treating and preventing HIV infection in younger children: report of the WHO Paediatric Antiretroviral Working Group.2008. (Updated 20 January 2008. Accessed 10 December 2012.) Available from http://www.who.int/hiv/pub/paediatric/ARV_WG_meeting_report_may2008.pdf.
29.
World Health Organization.Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach – 2010 revision.2010. (Updated 13 July 2010. Accessed 1 December 2012.) Available from http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf.
